A
AMETEK, Inc.
AME · Industrials
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
The Finest Industrial Compounder Money Can Currently Overbuy
The market has correctly identified AMETEK as exceptional, then priced in a decade of flawless execution before a single acquisition closes — the quality premium is deserved, but its magnitude assumes no friction in a machine that depends on a finite and increasingly contested acquisition pipeline.
Flowly Score
Apr 16 Close
-26%$230.24
Fair Value
$170.00
57
Averageat $230.24
Business Strength8/10
A genuine compounder built on switching costs and regulatory lock-in — FAA certifications and mission-critical instrument approvals are moats wrapped in bureaucracy that no competitor can shortcut. Rising ROIC while deploying capital into acquisitions is the fingerprint of process power that most serial acquirers never achieve.
Financial Resilience9/10
Software-company cash economics inside an engineer's hard hat — FCF conversion above 113%, leverage at 1x EBITDA, and a near-perfect Piotroski score signal a business that generates real cash and barely notices its capital requirements. The balance sheet preserves $5B+ of acquisition firepower without straining investment-grade ratings.
Growth & Trajectory7/10
Record backlog and orders establish a solid 2026 foundation, but the organic engine is grinding at low-to-mid single digits while acquisition-driven growth carries the headline number. The automation-and-precision-measurement flywheel is a genuine structural tailwind, but the compounding story increasingly depends on the M&A pipeline delivering.
Valuation3/10at $214.49
Every DCF scenario — optimistic included — implies meaningful downside from current levels, and EV/EBITDA has expanded above historical norms while organic growth has decelerated. The market is paying for the next five acquisitions before they happen, leaving essentially no margin of safety.
Risk6/10
The concrete risks are specific and underappreciated: export control exposure on dual-use precision instruments puts the fastest-growing geography directly in the crosshairs of US-China tech decoupling, and private equity has permanently raised the clearing price for the niche technical businesses AMETEK hunts. Neither is existential, but both compress the compounding rate if they materialize simultaneously.
AMETEK is exactly the kind of business that punishes you when you overpay for certainty. The price embeds low-to-mid single digit organic growth, several high-ROIC acquisitions not yet completed, and continued margin expansion from an already top-tier industrial base. Every DCF scenario implies material downside from current levels. This is a quality trap if organic momentum softens further or the acquisition environment stays competitive — and both risks are live simultaneously. The underlying business trajectory remains constructive. Record backlog, December orders that were the strongest single month in company history, and the structural flywheel of automation demanding ever-tighter measurement precision are all real. The FARO integration is a near-term margin drag, but the pathway from mid-teen to 30% EBITDA margins on a 3D measurement platform is credible for a management team that has run this playbook dozens of times. Asia's double-digit China rebound confirms the semiconductor and process demand recovery is happening, not hoped for. The single biggest named risk is export control expansion into dual-use precision instruments. AMETEK's metrology, spectroscopy, and semiconductor analytics tools sit precisely in the technology categories where Entity List restrictions materialize with almost no warning. Asia has been gaining revenue share for years — it is the growth engine. A meaningful export control action targeting semiconductor process metrology doesn't just clip a quarter; it forecloses the fastest-growing end market at the exact moment the valuation requires it to accelerate.